{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:34:55Z","timestamp":1787646895158,"version":"build-2736575974"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,25]]},"DOI":"10.7759\/cureus.8836","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T01:04:35Z","timestamp":1593133475000},"source":"Crossref","is-referenced-by-count":2,"title":["Pembrolizumab: An Immunotherapeutic Agent Causing Endocrinopathies"],"prefix":"10.7759","author":[{"given":"Abdul","family":"Chaudry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misbat","family":"Chaudry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonaid","family":"Aslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.2015.1074862","article-title":"Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma","volume":"15","author":"Faghfuri E","year":"2015","unstructured":"Faghfuri E, Faramarzi MA, Nikfar S, Abdollahi M. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma. Expert Rev Anticancer Ther. 2015, 15:981-993. 10.1586\/14737140.2015.1074862","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160221","article-title":"Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports","volume":"11","author":"Abdel-Wahab N","year":"2016","unstructured":"Abdel-Wahab N, Shah M, Suarez-Almazor ME . Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports. PLoS One. 2016, 11:0160221. 10.1371\/journal.pone.0160221","journal-title":"PLoS One"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000060","article-title":"Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma","volume":"38","author":"Chan MM","year":"2015","unstructured":"Chan MM, Kefford RF, Carlino M, Clements A, Manolios N. Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma. J Immunother. 2015, 38:37-39. 10.1097\/cji.0000000000000060","journal-title":"J Immunother"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1085w","article-title":"Autoimmune diabetes associated with pembrolizumab: a review of published case reports","volume":"9","author":"Cheema A","year":"2018","unstructured":"Cheema A, Makadia B, Karwadia T, Bajwa R, Hossain M. Autoimmune diabetes associated with pembrolizumab: a review of published case reports. World J Oncol. 2018, 9:1-4. 10.14740\/wjon1085w","journal-title":"World J Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-217454","article-title":"Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma","volume":"2016","author":"Aleksova J","year":"2016","unstructured":"Aleksova J, Lau PK, Soldatos G, McArthur G. Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma. BMJ Case Rep. 2016, 2016:bcr2016217454. 10.1136\/bcr-2016-217454","journal-title":"BMJ Case Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/34817-pembrolizumab-an-immunotherapeutic-agent-causing-endocrinopathies","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:18:43Z","timestamp":1707506323000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/34817-pembrolizumab-an-immunotherapeutic-agent-causing-endocrinopathies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,25]]},"references-count":5,"URL":"https:\/\/doi.org\/10.7759\/cureus.8836","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,25]]}}}